

PORTFOLIO FEATURES

Inception	8 July 2024
Benchmark Index	S&P/ASX300 Accumulation Index
No of holdings	28 (Maximum 35)
Quest AUM	\$1,088m
Investment horizon	3 - 5 years
Investment Strategy	Fundamental with a focus on business quality and free cash flow
Derivatives/Shorting	Nil
AFSL	279207



Lonsec Rating

STOCK PERFORMANCE AUGUST 2025

POSITIVE

Vault Minerals	+47%
Northern Star	+21%
Qoria	+12%
Origin Energy	+8%
NAB	+8%

NEGATIVE

CSL	-21%
Wisetech	-15%
Ramsay Health	-13%
Amcor	-11%

CONCENTRATED PORTFOLIO AUGUST 2025

The **ASX 300** climbed another 3.2% in August, marking the fifth straight month of gains. The index has advanced 16% since its last negative month in March. The **S&P 500** rose 3.2% however the tech-biased **NASDAQ** index managed only +1.6%. **China** (MSCI) +4.2% again outperformed as did **Japan** +4.0%. The **UK** FTSE +0.6% was more muted and **Germany** (DAX) fell -0.7%. Government 10-yr bond yields in both in the US and Australia barely moved. The Australian dollar rose +1.7%. On the ASX Value as a factor returned +7%, well ahead of Growth, which fell -3%.

The latest domestic reporting period saw even greater price volatility than usual, producing wide differences in returns. We comment on this over the page. Small caps +8.4% and mid-caps +5.5% outperformed the top 50 stocks, which rose 2.1%. Overall ASX 300 earnings forecasts continue to be cut, with margin pressure in a number of sectors. However, post reporting season downgrades, aggregate ASX 300 EPS for FY26 is forecast to lift 12.5%, with **Health**, **Industrial** and **Consumer Discretionary** sectors the major contributors. RBA rate cuts are lifting consumer activity.

Over 56% (by weight) of the Quest portfolio reported earnings that met or exceeded our expectations, whilst 24% did not report. That leaves 12% that disappointed, prominently **CSL** -21%, **Wisetech** -15%, **Ramsay Healthcare** -13% and **Amcor** -11%. These falls and lacklustre trading in **Immutep** -13% and **Catapult** -6% weighed on portfolio returns. Best performers were gold miners **Vault Minerals** +47% and **Northern Star** 21%, along with small cap **Qoria** +12, **Origin** and **NAB**, both +8%.

Gold provides an interesting counterbalance to the optimism seen in global equity markets. The \$US gold price is now more than 100% higher than two years ago, highlighting the continual deterioration in global government balance sheets and geopolitical uncertainties.

Whilst lower interest rates should provide support, markets have now marched to record highs in a sustained, five-month rally. We are being careful to contain portfolio risk, taking profits in growth-oriented names and tilting towards defensive stocks. We are well placed to capitalise should there be any market weakness, with room made available in the portfolio.

Performance*				
To 31 August 2025	1 month	3 months	1year	Since inception (pa)
Quest Concentrated Aust Equities	1.5%	6.2%	4.8%	6.7%
ASX300 Accumulation index	3.2%	7.2%	14.9%	17.4%
Value added	-1.7%	-1.0%	-10.1%	-10.7%

* Inception 08 July 2024. Fund performance and value added is net of all fees. **Past performance is no guarantee of future performance.** Returns for periods 1year or greater are calculated on an annualised basis.



'GALE FORCE VOLATILITY'


The chart below from JPMorgan highlights the increasing volatility of reporting season. It measures the portion of companies with material value adjustments post reporting, even on minor earning adjustments. The second half of FY25 was the most volatile in 20 years, and well above the average of the last five years.

Amcor is but one example. Expectations for Amcor's future results were low prior to reporting, as seen in the FY26 PE of 11x, half the current inflated ASX Industrials average of 21x. Post reporting, EPS for FY26 and FY27 had dropped ~2.5% but Amcor's shares finished August more than 10% lower.

Momentum factors continue to control market returns but we note a sign of change. CBA's FY25 result was in line with expectations but the market capitalisation has dropped \$42bn from the ridiculous \$191 per share seen at the end of June to \$165 currently.

Valuation gravity isn't a myth. Eventually a company's ability to generate cash will be reflected in its share price, regardless of the most recent profit, Index or ETF adjustment. Quest recognises the increasing influence of these factors. Perversely, passive investing is boosting market volatility. Quest continues to balance risk and return in portfolio holdings. During the month further gains were realised in Catapult and Qualitas.

CHART OF THE MONTH



INVESTMENT PROFILE

The Quest Concentrated Australian Equities Portfolio is a Unit Trust, actively managed by Quest Asset Partners Pty Limited. Our objective is to outperform the S&P/ASX300 Accumulation Index.

Disclaimer

Equity Trustees Limited ("Equity Trustees") ABN 46 004 031 298 | AFSL 240975, is the Responsible Entity for the Quest Concentrated Australian Equities Fund ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). The Investment Manager for the Fund is Quest Asset Partners Pty Ltd ("Quest") (ABN 47 109 448 802), AFSL 279 207. This publication has been prepared by Quest to provide you with general information only. In preparing this document, Quest did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Quest, Equity Trustees nor any of their related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should consider the Product Disclosure Statement ("PDS") before making a decision about whether to invest in this product.

Quest Concentrated Australian Equities Fund's Target Market Determination is available here www.eqt.com.au/insto. A Target Market Determination describes how this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed.

The rating issued 10/2024 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2024 Lonsec. All rights reserved.

KEY PORTFOLIO HOLDINGS

LARGE CAP

Aristocrat Leisure	ANZ
BHP	National Australia Bank
CSL	Origin Energy

MID CAP

Xero	Resmed
ALS	Block
Mirvac	Judo Capital

SMALL CAP

Qualitas	Maas Group
Catapult	Ventia Services

CONTACT THE MANAGERS

Michael Evans ph.02 9409 2300
mevans@questap.com.au

Troy Cairns ph.02 9409 2303
tcairns@questap.com.au

Swapna Pandya ph.02 9409 2302
spandya@questap.com.au